Ocugen Provides an Update on its COVAXI Pediatric (2-18) Emergency Use Authorization Request

Ocugen

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) recently announced that the U.S. Food and Drug Administration (FDA), at this time, has declined to issue an EUA for COVAXIN™ for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.

Ocugen states that it intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN™.

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.

READ:  COVID-19 Tax Filing Penalty Relief: Filing Deadline Is September 30, 2022